Financial Performance - The company's operating revenue for 2024 was CNY 2,467,418,394.64, a decrease of 5.48% compared to CNY 2,610,550,120.98 in 2023[18] - The net profit attributable to shareholders for 2024 was CNY -299,157,116.72, representing a decline of 213.63% from CNY 263,273,179.73 in 2023[18] - The basic earnings per share for 2024 was CNY -0.36, a decrease of 212.50% from CNY 0.32 in 2023[18] - The company reported a significant increase in the net profit after deducting non-recurring gains and losses, which was CNY -260,312,696.31 in 2024, down 185.41% from CNY 304,777,222.28 in 2023[18] - The weighted average return on net assets for 2024 was -7.24%, a decrease of 13.82% from 6.58% in 2023[18] - The company acknowledged uncertainties regarding its ability to continue as a going concern due to negative net profits in the recent accounting periods[18] Cash Flow and Investments - The net cash flow from operating activities increased by 77.24% to CNY 337,842,262.04 in 2024, compared to CNY 190,613,632.04 in 2023[18] - The company reported a significant increase in investment activity cash inflow, which rose by 270.30% to CNY 1,593,659,455.39 in 2024 from CNY 430,369,798.46 in 2023[91] - The cash flow from financing activities showed a significant decline, with a net outflow of CNY -562,171,817.13 in 2024 compared to a net inflow of CNY 841,717,750.30 in 2023, marking a decrease of 166.79%[91] - The company has obtained drug registration certificates for multiple products, which is expected to positively impact market share and future sales, although uncertainties remain regarding production and sales[88] Research and Development - The company has invested over 10% of its annual revenue in R&D for the past three years, with a total R&D team exceeding 400 members[48] - The total R&D expenditure decreased by 19.28% to CNY 263,460,034.52 in 2024 from CNY 326,396,807.54 in 2023, with the R&D expenditure as a percentage of operating revenue dropping to 10.68% from 12.50%[89] - The company is focusing on the development of innovative drugs for metabolic and respiratory diseases, with significant progress in clinical trials and regulatory approvals[44] - The company has established a multi-mode R&D ecosystem focusing on independent research and development, supplemented by collaborative efforts to meet significant clinical needs[40] - The company is committed to exploring new drug development and revitalizing dormant products, leveraging policy opportunities for growth[35] Market and Industry Trends - The pharmaceutical industry is experiencing a shift towards innovation-driven growth, supported by government policies and technological advancements[28] - In 2024, over 270 national-level policies and approximately 1300 provincial-level policies related to the pharmaceutical industry were released, creating a favorable external environment for industry development[29] - The total revenue of the pharmaceutical manufacturing industry in China for 2024 was ¥2,529.85 billion, showing no growth compared to the previous year[28] - The total profit of the pharmaceutical manufacturing industry decreased by 1.1% year-on-year to ¥342.07 billion in 2024[28] Product Development and Innovation - The company focuses on innovative drug research and development in metabolic and respiratory diseases, maintaining a leading position domestically[33] - The company’s innovative drug, Lai Ru Te Wei Tablets, is the world's first oral drug targeting COVID-19, included in the expert consensus for clinical application in 2024[36] - The company has a robust product pipeline and actively expands sales channels, including online sales and third-party terminals, to enhance market reach[34] - The company’s products cover major disease areas such as cardiovascular, respiratory, ophthalmology, and digestive diseases, with a continuous optimization of product structure[32] - The company is committed to the internationalization of its innovative drugs, supported by government policies that enhance R&D and market application[119] Corporate Governance and Investor Relations - The company has established a comprehensive investor relations management system[139] - The company has taken effective measures to protect the legal rights of investors[137] - The company emphasizes investor relations, implementing various communication methods, including performance briefings and dedicated investor hotlines, to enhance transparency and engagement[143] - The company has established a transparent performance evaluation system for directors and senior management, linking their compensation to company performance and individual achievements[144] - The company has implemented a cash repurchase program as part of its strategy to return value to shareholders[142] Strategic Planning and Future Outlook - The company plans to enhance its market position by focusing on innovative drug development and optimizing its product pipeline in response to national policies promoting the biopharmaceutical industry[113] - The company aims to solidify its core prescription drug business and face new challenges by 2025[126] - The company is expected to continue its growth trajectory with strategic management changes and a focus on market expansion[152] - The company plans to enhance production capacity and supply chain operations, aiming for refined management of quality, efficiency, and costs in its manufacturing sector[129] - The company is actively pursuing strategic adjustments across R&D, production, and sales to enhance competitiveness in a slowing industry environment[41] Employee and Talent Management - The total number of employees at the end of the reporting period was 1,775, with 714 in the parent company and 1,061 in major subsidiaries[176] - The company emphasizes talent development through structured training plans for different employee levels, ensuring a robust talent pipeline[181] - The annual training plan focuses on enhancing professional skills and knowledge, with quarterly legal training sessions for key personnel[179] - The company has established a "Five-Star Team" evaluation standard to improve production efficiency and team management, with assessments conducted quarterly[180] - The company has implemented a tiered salary mechanism based on functional contributions, ensuring internal fairness and external competitiveness in compensation[178]

Financial Performance - The company's revenue for Q1 2025 was CNY 634,261,440.11, a decrease of 1.07% compared to the same period last year[5] - Net profit attributable to shareholders increased by 61.06% to CNY 82,611,839.10 compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 78,434,825.55, an increase of 8.60% year-on-year[5] - Basic and diluted earnings per share rose by 66.67% to CNY 0.10 per share[5] - Net profit for the current period is ¥81,448,217.01, an increase of 67.24% compared to ¥48,710,926.21 in the previous period[24] - Comprehensive income for the current period is ¥78,613,417.36, compared to ¥49,316,011.34 in the previous period, an increase of 59.53%[25] Cash Flow - The net cash flow from operating activities improved by 63.98%, reaching CNY -28,614,967.91[5] - The net cash flow from operating activities was -$28.61 million, an improvement from -$79.45 million in the previous period[27] - Cash inflow from operating activities totaled ¥412,758,125.62, down from ¥438,885,971.29, a decrease of 5.95%[26] - The net cash flow from investing activities decreased by 79.66% to ¥18,041,267.34, primarily due to changes in the purchase and recovery of bank deposit products during the reporting period[11] - The net cash flow from financing activities decreased by 34.68% to -¥397,557,854.76, mainly due to payments for share buybacks and the repayment of bank loans in the same period last year[11] - The net cash flow from investment activities was $18.04 million, a decrease from $88.72 million year-over-year[27] - The net cash flow from financing activities was -$397.56 million, worsening from -$295.20 million in the previous period[27] Assets and Liabilities - Total assets decreased by 5.78% to CNY 5,232,775,325.09 compared to the end of the previous year[5] - As of March 31, 2025, the total assets of the company amounted to RMB 5.23 billion, a decrease from RMB 5.55 billion at the beginning of the period[22] - The company’s total liabilities decreased from RMB 1.54 billion to RMB 1.14 billion, reflecting a significant reduction in financial obligations[22] - Current assets totaled RMB 3.14 billion, down from RMB 3.46 billion, indicating a decline in liquidity[21] - Cash and cash equivalents decreased from RMB 1.40 billion to RMB 990.26 million, showing a reduction in available cash[20] - The company’s short-term borrowings increased from RMB 303.46 million to RMB 353.26 million, indicating a rise in short-term debt[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 91,109[14] - The company’s major shareholders, Zhang Yuchong and Zhang Yuli, each hold 10.88% of the shares, with significant portions pledged[14] Research and Development - Research and development expenses decreased by 46.87% to ¥15,923,565.59, mainly due to the large external research progress payments made in the same period last year[11] - Research and development expenses decreased significantly to ¥15,923,565.59 from ¥29,971,407.45, a reduction of 46.94%[23] - The company’s subsidiary, Guangdong South China Pharmaceutical Group, received approval for its brain embolism capsule as the first secondary protected traditional Chinese medicine, with a protection period of seven years starting from the announcement date[15] - The company’s subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., received FDA approval for the clinical trial of the innovative peptide drug RAY1225, which targets obesity and type 2 diabetes[16] - RAY1225 is set to enter Phase III clinical trials, with ethical approval obtained from key institutions, indicating significant progress in its development[16] Other Income and Expenses - Other income increased by 182.18% to ¥9,079,567.10, attributed to an increase in government subsidies received during the reporting period[11] - Tax expenses rose to ¥17,814,054.06 from ¥10,405,699.02, an increase of 71.00%[24] - Sales expenses increased to ¥218,567,447.02 from ¥213,627,193.97, an increase of 2.18%[23] Strategic Focus - The company aims to enhance operational efficiency and profitability through strategic focus on core business segments and cost control upgrades in 2025[9] - The company reported a significant improvement in operational indicators, laying a foundation for high-quality development throughout the year[9] Accounting and Audit - The company did not undergo an audit for the first quarter report[28] - The new accounting standards will be implemented starting in 2025[28]

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

证券代码：002317 公告编号：2025-026 广东众生药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 广东众生药业股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开 了第八届董事会第十五次会议及第八届监事会第十五次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金 投资计划正常进行的情况下，使用不超过人民币 28,000.00 万元的闲置募集资金 进行现金管理，适时购买结构性存款、大额存单等安全性高的保本型产品。现金 管理期限为本次董事会审议通过之日起十二个月内。在上述额度和期限内资金可 滚动使用，但在任一时点的实际投资金额不超过人民币 28,000.00 万元，本次使 用部分闲置募集资金进行现金管理事项将在上述额度内，授权董事长具体实施相 关事宜。 上述具体内容详见公司于 2024 年 8 月 30 日刊载在《证券时报》和巨潮资讯 网（www.cninfo.com.cn）的相关公告。 为提高募集资金使用效率，在确保不影 ...

证券代码：002317 公告编号：2025-025 广东众生药业股份有限公司 关于公司股东部分股份解除质押的公告 证券代码：002317 公告编号：2025-025 一、股东股份本次解除质押的基本情况 二、股东股份累计质押的情况 截至本公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | | 本次变动 | 本次变动 | 占其 | 占公 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股数量 | 持股 | 前质押股 | 后质押股 | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | 名称 | （万股） | 比例 | 数（万 | 数（万 | 股份 | 股本 | 份限售和 | 质押 | 份限售和 | 质押 | | | | | 股） | 股） | 比例 | 比例 | 冻结数量 | 股份 | 冻结数量 | 股份 | | | | | | | | | （万股） | 比例 | （万股） | 比例 | | 张玉冲 | 9,264.05 ...

培训情况报告 华泰联合证券有限责任公司关于 广东众生药业股份有限公司持续督导期 2024年培训情况报告 深圳证券交易所： 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作为 广东众生药业股份有限公司（以下简称"众生药业"、"公司"）向特定对象发行 股票并在主板上市的保荐人，根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》、《深圳证券交易所股票上市规则》和《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等法规和规则的相关规 定以及众生药业的实际情况，认真履行保荐机构应尽的职责，对众生药业的董事、 监事、高级管理人员、主要中层以上管理人员及上市公司实际控制人等相关人员 进行了有计划、多层次的后续培训，所培训的内容严格按照中国证券监督管理委 员会及深圳证券交易所有关持续督导的最新要求进行。 2025 年 3 月 26 日，华泰联合证券相关人员按照《深圳证券交易所上市公司 自律监管指引第 13 号——保荐业务》的要求完成了对众生药业董事、监事、高 级管理人员、主要中层以上管理人员及上市公司实际控制人等相关人员的持续培 训工作，特向贵所报送培训工作报告。 一 ...

现场检查报告 | （如适用） | | | --- | --- | | 3.内部审计部门和审计委员会的人员构成是否合规（如适用） | √ | | 4.审计委员会是否至少每季度召开一次会议，审议内部审计部门提交的 | √ | | 工作计划和报告等（如适用） | | | 5.审计委员会是否至少每季度向董事会报告一次内部审计工作进度、质 | √ | | 量及发现的重大问题等（如适用） | | | 6.内部审计部门是否至少每季度向审计委员会报告一次内部审计工作 | √ | | 计划的执行情况以及内部审计工作中发现的问题等（如适用） | | | 7.内部审计部门是否至少每季度对募集资金的存放与使用情况进行一 | √ | | 次审计（如适用） | | | 8.内部审计部门是否在每个会计年度结束前二个月内向审计委员会提 | √ | | 交次一年度内部审计工作计划（如适用） | | | 9.内部审计部门是否在每个会计年度结束后二个月内向审计委员会提 | √ | | 交年度内部审计工作报告（如适用） | | | 10.内部审计部门是否至少每年向审计委员会提交一次内部控制评价报 | √ | | 告（如适用） | | | 11.从事 ...

张玉立女士上述质押股份不存在负担重大资产重组等业绩补偿义务的情况。 证券代码：002317 公告编号：2025-024 广东众生药业股份有限公司 关于公司股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）近日接到公司持股5%以上 股东张玉立女士关于其部分股份进行股票质押式回购交易的通知，具体事项如下： | 股东名称 | 是否为控股 | 本次质押 股份数量 | 占其所 持股份 | 占公 | 是否 为限 | 是否 | | | 质权人 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股东或第一 | | | 司总 | | 为补 | 质押起 | 质押到 | | 质押 | | | 大股东及其 | | | 股本 | | 充质 | 始日 | 期日 | | 用途 | | | 一致行动人 | （万股） | 比例 | 比例 | 售股 | 押 | | | | | | 张玉立 | 公司控股股 东的一致行 | 871.0 ...

证券代码：002317 公告编号：2025-023 广东众生药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 广东众生药业股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开 了第八届董事会第十五次会议及第八届监事会第十五次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金 投资计划正常进行的情况下，使用不超过人民币 28,000.00 万元的闲置募集资金 进行现金管理，适时购买结构性存款、大额存单等安全性高的保本型产品。现金 管理期限为本次董事会审议通过之日起十二个月内。在上述额度和期限内资金可 滚动使用，但在任一时点的实际投资金额不超过人民币 28,000.00 万元，本次使 用部分闲置募集资金进行现金管理事项将在上述额度内，授权董事长具体实施相 关事宜。 上述具体内容详见公司于 2024 年 8 月 30 日刊载在《证券时报》和巨潮资讯 网（www.cninfo.com.cn）的相关公告。 为提高募集资金使用效率，在确保不影 ...

Investment Rating - The industry investment rating is "Recommended" [1] Core Insights - The report highlights the impact of escalating trade conflicts on the supply chain of pharmaceuticals, particularly regarding the exemption of certain drugs from tariffs, which reflects the U.S.'s reliance on global pharmaceutical supply chains [3] - The report emphasizes the importance of international markets for Chinese pharmaceutical exports, with a projected export value of $107.96 billion in 2024, indicating a growth of 5.9% year-on-year [4] - The report discusses the potential changes in the supply landscape for blood products due to new tariffs, which may accelerate domestic substitution opportunities [6] - The report notes the ongoing evolution of raw material applications, particularly in the nicotine sector, as companies explore new production avenues [8] - The report indicates that the optimization of centralized procurement policies may alleviate pricing pressures on traditional pharmaceutical companies [10] - The report outlines advancements in CAR-T cell therapies, with significant sales growth and the potential for cost reductions in the future [12] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.57 percentage points in the past week, ranking third among 31 primary industry indices [23] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's index has shown a 3.15% increase over the past month, outperforming the CSI 300 index by 4.20 percentage points [40] - The current PE (TTM) for the pharmaceutical sector is 31.25, which is below the historical average of 32.95 [45] 3. Recent Research Achievements - The report lists various deep-dive studies conducted by the research team, focusing on supply and demand dynamics in the blood products sector and the impact of policy support on inhalation drug markets [49] 4. Important Industry Policies and News - Recent policy updates include the release of the 2025 edition of the Pharmacopoeia of the People's Republic of China, which will take effect on October 1, 2025 [52] - Significant industry news includes the approval of new drug applications by major pharmaceutical companies, indicating ongoing innovation and market activity [54][55]